200 Pier Four Boulevard
About Servier Pharmaceuticals
Servier Pharmaceuticals is a commercial-stage pharmaceuticals company with a passion for innovation and improving the lives of patients, their families and caregivers. In the United States, Servier Pharmaceuticals is committed to building a robust portfolio, starting with oncology, with future growth driven by innovation in other areas of unmet medical need, leveraging Servier's global portfolio and seeking acquisitions, licensing deals and partnerships. Servier Pharmaceuticals believes co-creation is fundamental to driving innovation and is actively building alliances that bring solutions to patients' lives and can accelerate access to therapies. We are building relationships with academia, venture capitalists, biotech and pharmaceutical peers and advocates with the aim of entering into mutually beneficial and complementary partnerships where each organization's skill sets are recognized and leveraged for the benefit of patients. With our commercial and scientific expertise, global reach and commitment to clinical excellence, Servier Pharmaceuticals is dedicated to bringing the promise of tomorrow to the patients that we serve.
Servier is committed to serving patient needs. We work every day with passion for therapeutic progress to save and treat patients; It is our vocation. #WeAreServier
7 articles with Servier Pharmaceuticals
Servier, a growing leader in oncology committed to bringing the promise of tomorrow to the patients we serve, announced that data will be presented from multiple studies across its oncology portfolio during the 2021 American Society of Clinical Oncology Virtual Annual Meeting, June 4-8 and the European Hematology Association 2021 Virtual Congress, June 9-17.
Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO® (ivosidenib tablets) in IDH1-mutated Cholangiocarcinoma
Servier Pharmaceuticals, a leader in hematology, achieves first major milestone in the solid tumor category Company has grown U.S. oncology business by nearly 20% in the past two years
Servier was found guilty of manslaughter and deceptive marketing practice for its weight-loss pill Mediator. The Paris-based company was fined $3.12 million following a lawsuit that took years to wind its way through the court system.
Servier and MiNA Therapeutics are partnering on small activating RNA (saRNA) therapies to treat neurological diseases. saRNA is an entirely new class of drugs.
The company bolstered its presence in oncology with the acquisition of the clinical and research-stage oncology business of Agios in a deal worth up to $2 billion.
10/19/2020It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. Here’s a look.
10/16/2020Galapagos NV and Servier reported that their ROCELLA Phase II clinical trial of GLPG1972/S201086 failed to meet its primary endpoint in osteoarthritis knee repair.